Boehringer and Geisinger to develop risk-prediction model for type 2 diabetes health outcomes

Boehringer Ingelheim, on behalf of its diabetes alliance with Eli Lilly and Company, has entered a collaboration with Geisinger to develop a risk-prediction model for three critical health outcomes commonly associated with type 2 diabetes.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news